A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell Carcinoma.
BACKGROUND
Basal cell carcinoma (BCC) is the most common form of skin cancer; however, few data are available relating to patients' perspectives and experiences of this disease. This study explored the spectrum of BCC symptoms and their impact by disease stage to determine how BCC affects the overall health-related quality of life (HRQL) of patients.


METHODS
This study comprised a cross-sectional, qualitative approach involving telephone interviews with patients with BCC who had been divided into two groups: group 1 (G1), patients with stage 1, non-advanced BCC (and of superficial or nodular histology); and group 2 (G2), patients with locally advanced or metastatic BCC. Patients were recruited from three clinical sites in the USA based on a separate qualitative interview study (I4J-MC-HHBB [1.3]) over a 10-month period. Techniques in qualitative methodology were used by applying 'open-ended' questions and probing techniques intended to elicit patients' own description of their experiences with BCC. Telephone interviews lasted between 60 and 90 mins.


RESULTS
Thirty-four interviews were conducted (G1: N = 13; G2: N = 21). The majority of patients were aged either 55-64 years (32%, N = 11) or 76+ years (32%, N = 11) and were primarily male (82%, N = 28); most (75%, N = 24) patients were actively receiving BCC treatment. Both groups reported similar symptoms, with the most common being red lesions or open sores that failed to heal (41%, N = 14) and cancer-related stress (41%, N = 14). G2 reported more frequent and severe HRQL impact as a result of their cancer condition because most were affected in their daily activities (76%, N = 16) or emotional well-being (71%, N = 15). Cosmetic and functional impacts were relevant and important aspects of HRQL for both patient groups (G1: 31%, N = 4; G2: 48%, N = 10).


CONCLUSIONS
Patients with non-advanced or locally advanced and metastatic BCC experience disease-related symptoms that affect their HRQL, activities of daily living, emotional well-being, and social and/or leisure activities. Qualitative descriptions of patient experiences can help healthcare providers and caregivers better understand the impact of BCC from the patient perspective.


BACKGROUND
Eli Lilly and Company.
Evidera, Bethesda, MD, USA.
Anna W
AW
Steenrod
Early Phase Medical, Oncology, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. Nash_smyth_emily@lilly.com.
Emily Nash
EN
Smyth
Early Phase Medical, Oncology, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Elizabeth N
EN
Bush
Stanford University, Stanford, CA, USA.
Anne Lynn S
AL
Chang
University of California San Francisco, San Francisco, CA, USA.
Sarah T
ST
Arron
University of Michigan, Ann Arbor, MI, USA.
Yolanda R
YR
Helfrich
Translational Genomics Research Institute, HonorHealth, Phoenix and Scottsdale, Phoenix, AZ, USA.
Daniel D
DD
Von Hoff
Early Phase Medical, Oncology, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.|Infinity Pharmaceuticals, Cambridge, MA, USA.
Leslie H
LH
Brail
Evidera, Bethesda, MD, USA.
Karin S
KS
Coyne
Basal cell carcinoma (BCC); Dermatology; Health-related quality of life (HRQL); Locally advanced; Metastatic; Non-advanced BCC; Non-melanoma skin cancer (NMSC); Qualitative; Symptomatology